Outcome and target group of the MIND program
Who should join MIND?
Master of Industrial Drug Development (MIND) is aimed at experienced people in the biotech and pharmaceutical industries, clinical research organizations, and to some extent the medico industry, who are involved in developing drugs and need an overview of the process in its entirety as well as in-depth understanding of the individual elements. Training is tailored to project managers, group managers, divisional managers, researchers and others who have - or expect to have - responsibility for several aspects of the drug development process.
The typical participant has a background in fields such as engineering, pharmacy, chemistry, biochemistry or the health sciences. Commitment and interest in meeting professional challenges are requirements for the Master of Industrial Drug Development program.
Applicants enrolling in the MIND program or individual courses must have at least a relevant bachelor's degree or equivalent followed by a minimum of two years of relevant job experience. Proficiency in English is a prerequisite.
Why join MIND?
With pharmaceutical companies striving to be market leaders, key employees must have a broad overview and the ability to understand the connections between all stages of the development process from discovery to marketing.
On completion of the program, Masters of Industrial Drug Development will have gained extensive interdisciplinary and practical knowledge of the industrial drug development process. Their ability to effectively and critically evaluate each stage of the drug development process will allow them to predict future bottlenecks.
The MIND program gives drug developers the professional building blocks to be able to create and lead teams across divisional lines. Masters of Industrial Drug Development will be able to liaise with other professionals within the company as well as with external partners, thus ensuring a high and up-to-date scientific level of the work carried out in multidisciplinary project teams.
